Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 19/20 | 0.47 |
| ▸ | ITGAV | P06756 | 19/20 | 0.47 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.40 |
| ▸ | WDR5 | P61964 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7038300 | 0.96 | ITGB3 (0.53) | ITGB3ITGAVITGA2B | |
| SCHEMBL7035985 | 0.94 | ITGB3 (0.50) | ITGB3ITGAVITGA2B | |
| SCHEMBL7037116 | 0.90 | ITGB3 (0.56) | ITGB3ITGAVITGA2B | |
| SCHEMBL7254032 | 0.89 | ITGB3 (0.51) | ITGB3ITGAVITGA2B | |
| SCHEMBL7038297 | 0.88 | ITGB3 (0.49) | ITGB3ITGAVITGA2B | |
| SCHEMBL7037154 | 0.88 | ITGB3 (0.50) | ITGB3ITGAVITGA2B | |
| SCHEMBL7029512 | 0.88 | ITGAV (0.50) | ITGB3ITGAVITGA2B | |
| SCHEMBL7036093 | 0.88 | ITGB3 (0.47) | ITGB3ITGAVITGA2B | |
| SCHEMBL7038299 | 0.88 | ITGB3 (0.46) | ITGB3ITGAVITGA2BWDR5 | |
| SCHEMBL7036500 | 0.87 | ITGB3 (0.52) | ITGB3ITGAVITGA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030186967-A1 | Acylresorcinol derivatives are selective vitronectin receptor inhibitors | AMERICAN HOME PRODUCTS CORPORATION (US) | 2003-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030186967-A1 | Acylresorcinol derivatives are selective vitronectin receptor inhibitors | ASGR1, TEK, APLNR | ITGB3 403/4885ITGAV 289/4885ITGA2B 573/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.